Vimian Group AB
The answer first
Does Vimian Group beat the market?
Yes, Vimian Group has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 65% of Nordic stocks
- Quality58
- Value22
- Trend95
No. 43 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Vimian Group keeps must grow about 8% a year for 10 years.
Max for seven days
Follow Vimian Group with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Vimian Group
Your first answer is free, no account needed.
Do you own Vimian Group, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Vimian Group and a few more. Free, no card.
Super Stock+44.6%In short
- Vimian Group has risen 46.5% over the past year, including dividends.
- Overall, Vimian Group ranks better than 65% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 79.7%. The price is 62.9% below its peak now.
What do analysts think of Vimian Group?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 65% of Nordic stocks.
No. 43 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 113 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.38
- Asset turnoverSales divided by everything the company owns0.39
- Return on equityProfit divided by equity+5.2%
- Cash conversionOperating cash flow divided by profit2.69
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 94 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.7
- P/SPrice divided by sales4.3
- P/EPrice divided by earnings51.5
- P/CFPrice divided by operating cash flow19.1
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 12 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+24.8%
- 6 months+50.8%
- 9 months+63.2%
- 12 months+46.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Vimian Group
15 funds we follow own Vimian Group. The share is how much of the fund the stock makes up.
- Norway1
- Sweden13
- Denmark1
- TIN Småbolag ASweden · TIN4.7%
- PLUS Hälsovård Sverige IndexSweden · PLUS4.4%
- Case All StarSweden · Case3.9%
- Wealth Inv I&T Nord AktLargeCaDenmark · Wealth Invest1.6%
- AMF Aktiefond SmåbolagSweden · AMF1.3%
- Handelsbanken Nordiska Småbol (A1 NOK)Sweden · Handelsbanken0.6%
- PLUS Småbolag Sverige IndexSweden · PLUS0.5%
- Folksam LO SverigeSweden · Folksam0.4%
Show all 15
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.2%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.2%
- Öhman Etisk Index Sverige ASweden · Öhman0.1%
- Avanza Sweden All Cap ASweden · Avanza0.1%
- PLUS Allabolag Sverige IndexSweden · PLUS0.1%
- Skandia Sverige ExponeringSweden · Skandia0.1%
- KLP AksjeNorden IndeksNorway · KLP0.0%
From the funds' latest known holdings.
About Vimian Group
Vimian Group AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1,000 employees.
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.


See the full analysis of Vimian Group.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card